Protect Access to Affordable Medications

Access to affordable compounded GLP-1 medications is essential for public health and health equity. GLP-1s have been proven to help manage not only diabetes but also obesity, a chronic condition that affects over 40% of adults in the U.S. and disproportionately impacts communities of color and low-income individuals. Limiting access to these medications reinforces a two-tiered healthcare system—where only those with wealth or certain diagnoses can receive potentially life-saving treatment, while millions are left behind. Compounded versions of GLP-1s provide a critical, lower-cost alternative that helps bridge this gap.

The current insurance coverage restrictions create unnecessary barriers that prevent people from proactively managing their health. People at risk for diabetes, heart disease, and other chronic conditions should not have to wait until they’re sick enough to qualify for treatment. This reactive approach is both morally unjust and economically short-sighted. Allowing broader access to affordable compounded GLP-1s would empower individuals to take control of their health earlier, reduce long-term healthcare costs, and ease the strain on an already overburdened medical system.

Equitable healthcare means ensuring that life-changing medications are not just available to the privileged few. By restricting compounded GLP-1s, we’re reinforcing cycles of poor health and poverty in vulnerable communities. Congress must protect access to affordable compounded GLP-1s to support a more just, preventative, and inclusive healthcare system—one that prioritizes outcomes over profit, and health over bureaucracy.